Lactobacillus Improves Helicobacter Pylori-associated Diseases

H. pylori

anti-

in vivo

and anti-inflammation

H. pylori

effects of two lactobacillus strains from the human stomach may indicate a possible new treatment for

-associated diseases.

World Journal of Gastroenterology

, the researchers divided 40

H. pylori

-infected Balb/c

Lactobacillus fermenti (L. fermenti)

proton pump inhibitor and antibiotics triple-treated group, a

Lactobacillus acidophilus

-treated group, a

-treated group, and a normal saline control group. Ten uninfected mice were included as a blank control group.

According to the study results, published in the mice into four groups: a

lactobacillus

The researchers wrote, “Histopathologic evaluation showed significant release of mucosal inflammation in gastric antrum and gastric body in

H. pylori

treated groups and triple treated group.

lactobacillus

eradication rate in both

Lactobacillus

treated groups and triple treated group were higher than normal saline control group.

H. pylori

treated groups and triple treated group showed significant decrease of

bacterial density.”

H. pylori

Rapid urease tests, Giemsa staining, and bacterial culture were used to identify

L. fermenti

infection, and the colonization of these bacteria “was assessed in bacterial density score and gastric inflammation was assessed in histological score.” The researchers used fluorescent probe to colonize

.

Lactobacillus fermenti

Both actobacillus strain

L. fermenti

(

Lactobacillus acidophilus

) and

L. acidophilus

(

H. pylori

) showed “significant” activity against

L. fermenti

. However,

in vivo

was found to have “more efficient antagonistic activity

,” with efficacy that was close to the rate produced by standard triple therapy.

New research on the potential